Three ways of tackling PD-1 resistance with different modalities plus an emerging biomarker of response
The route to success is often a winding track with unexpected obstacles
When the future of ADCs and bispecifics collide
Will 2024 be a 'Zeitenwende' moment for the IO field..
Which Thunderbirds are Go in this niche?!